Burroughs Wellcome and the Pricing of AZ...
Liedtka, Jeanne M.
Burroughs Wellcome and the Pricing of AZT (A)
E-0074 | Published April 15, 1991 | 9 pages Case
Collection: Darden School of Business
Product Details
This case focuses on the development of AZT, the first drug approved for the treatment of AIDS, and the issues faced by its U.K. producer, Wellcome PLC, as it decides how to set the drug's price. The case includes brief overviews of the disease itself, drugs in development to treat it, the pharmaceutical industry and its practices, and the history of Wellcome PLC and its U.S. subsidiary, Burroughs Wellcome. The A case concludes with analysts' predictions for the soon-to-be-announced price of AZT. See also the B case (UVA-E-0075) and the C case (UVA-E-0076).
0
Products to Upsell
Chains
Larson, Andrea
Terminal Values, Multiples, and Competit...
Harris, Robert S.
Leading with Vulnerability
Belmi, Peter; Thom...
Accounting for Owners’ Equity
Lynch, Luann J.; B...
Share Repurchases
Loutskina, Elena
Finance People
Schill, Michael J.
Ought to "Can": Questions for an Entrepr...
Sarasvathy, Saras ...
Jonathan Virginia, Inc.
Hess, Edward D.